Synlogic

Synlogic is dedicated to bringing innovative medicines to patients. Using Synlogic's synthetic biology platform, the company can engineer probiotics to perform specific therapeutic functions and establish connections with diseases. These Synthetic Biotics™ can be administered orally and function within the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. Synlogic also aims to deliver Synthetic Biotics directly to disease sites where localized activity is crucial, such as stimulating immune effectors to combat certain tumors.Synlogic can rapidly translate this groundbreaking science into medicines with the potential to transform patients' lives. The company’s lead programs target patients with rare genetic metabolic disorders, including Phenylketonuria (PKU) and secondary hyperoxaluria. Synlogic is also advancing research on Synthetic Biotics™ to address more prevalent conditions, including Inflammatory Bowel Disease (IBD), cancer, and other metabolic disorders.